SITE003-0293

completed

Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer Phase III · Site: SITE003 (CAN) (Dr. Okafor) · consented 2023-02-16

Adverse events

Serious AEs

Open data queries

Luna dropout signal

–

Adverse events

moderate assessed 2026-08-18

Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-03-24 (study day 29); relationship: not assessed

moderate assessed 2026-08-18

Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-04-04 (study day 40); relationship: N

severe serious assessed 2026-08-18

Grade 3 Fatigue — outcome: RECOVERED/RESOLVED; onset 2023-04-06 (study day 42); relationship: not assessed; serious criteria: hospitalization

moderate assessed 2026-08-18

Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-05-11 (study day 77); relationship: not assessed

mild assessed 2026-08-18

Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-06-24 (study day 121); relationship: not assessed

mild assessed 2026-08-18

Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-07-03 (study day 130); relationship: not assessed

severe serious assessed 2026-08-18

Grade 3 Asthenia — outcome: RECOVERED/RESOLVED; onset 2023-07-04 (study day 131); relationship: not assessed; serious criteria: hospitalization

Data queries

No data queries.

☾ Luna engagement

This participant doesn't use Luna.